

Response to: 'Tofacitinib for the treatment of polyarteritis nodosa: a literature review'. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar *et al*

We appreciate the interest of Akiyama *et al* in our report and thank them for the data presented in their letter.^{1,2} Akiyama *et al* have presented a thorough literature review and have described a positive and efficacious effect of tocilizumab in 11 cases of refractory polyarteritis nodosa (PAN) described in 6 case series. Indeed, the use of tocilizumab, an interleukin (IL)-6 inhibitor, in vasculitis is gaining evidence in the literature, specifically in large vessel vasculitis including giant cell arteritis and Takayasu arteritis.^{3,4} Nevertheless, it should be noted that although the IL-6 pathway is the major inducer of STAT 3, and therefore was used by us *in vitro* to stimulate this pathway in order to evaluate STAT 3 activation, clinically blocking the IL-6 pathway in our patient, using tocilizumab, was not beneficial, contrasting with our positive result with tofacitinib. We hypothesised that redundancy or other stimulators of the STAT 3 pathway like IL-23 may explain this discrepancy. Furthermore, we did not find tocilizumab clinically or radiologically beneficial in another patient with severe refractory PAN involving skin and coronary arteries—evidenced by positron emission tomography-CT scan revealing active inflammation in an aneurism within a coronary artery and by MRI demonstrating active deep skin involvement while under treatment with tocilizumab (unpublished data).

Thus, in considering the review by Akiyama *et al*, publication bias should always be considered when evaluating case reports, as we all tend to prefer publishing our positive experience.

Recently, we have also reported our positive experience with another agent, infliximab, for refractory PAN and reviewed the literature.⁵ The ever-expanding spectrum of biological treatments is confusing for the practitioner and although case reports and case series are important to guide us in rare refractory patients, we should still follow guidelines and use evidence-based treatments that were evaluated in large randomised controlled clinical trials as first-line therapy.

New technologies may help us diagnose and treat refractory patients. Whole-exome sequencing studies may reveal novel mimickers, the monogenic vasculitides, as deficiency of adenosine deaminase 2, stimulator of interferon genes-associated vasculopathy with onset in infancy, and haploinsufficiency of A20 that should be considered in refractory cases. Finally, precision medicine, as we suggested in our report, may guide us in the future, helping us to find the right fit for each patient.^{6,7}

Doron Rimar ,¹ Abid Awisat,¹ Lisa Kaly,¹ Gleb Slobodin,¹ Itzhak Rosner,¹ Michael Rozenbaum,¹ Shira Ginsberg,¹ Elina Starosvetsky,² Ayelet Alpert,³ Shai Shen-Orr³

¹Rheumatology, Bnai-Zion medical center, Haifa, Israel

²Department of Immunology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Haifa, Israel

³Department of Immunology, Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Correspondence to Dr Doron Rimar, Rheumatology, Bnai Zion Medical Centre, Haifa 31048, Israel; doronrimar@gmail.com

Handling editor Josef S Smolen

Twitter Doron Rimar @doronrimar@gmail.com

Contributors All authors were involved in writing, editing and approval of the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Rimar D, Awisat A, Kaly L, *et al*. *Ann Rheum Dis* 2022;**81**:e205.

Received 15 August 2020

Accepted 16 August 2020

Published Online First 9 September 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-218710>

Ann Rheum Dis 2022;**81**:e205. doi:10.1136/annrheumdis-2020-218790

ORCID iD

Doron Rimar <http://orcid.org/0000-0002-9137-2322>

REFERENCES

- 1 Akiyama M, Kaneko M, Takeuchi T. Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. *Ann Rheum Dis* 2022;**81**:e204.
- 2 Rimar D, Alpert A, Starosvetsky E, *et al*. Tofacitinib for polyarteritis nodosa: a tailored therapy. *Ann Rheum Dis* 2016;**75**:2214–6.
- 3 Stone JH, Tuckwell K, Dimonaco S, *et al*. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med* 2017;**377**:317–28.
- 4 Nakaoka Y, Isobe M, Tanaka Y, *et al*. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study [published online ahead of print, 2020 Jan 17]. *Rheumatology* 2020;kez630.
- 5 Ginsberg S, Rosner I, Slobodin G, *et al*. Infliximab for the treatment of refractory polyarteritis nodosa. *Clin Rheumatol* 2019;**38**:2825–33.
- 6 Ozen S, Batu ED. Vasculitis pathogenesis: can we talk about precision medicine? *Front Immunol* 2019;**10**:2018:9.
- 7 Csernok E, Hellmich B. Usefulness of vasculitis biomarkers in the era of the personalized medicine. *Autoimmun Rev* 2020;**19**:102514.